Effective Visual Communication (EVC) exercise: Case study

Efficacy of Capmatinib in Non Small Cell Lung Cancer (NSCLC) with MET mutations

Background:

Phase 2 study of Capmatinib (MET receptor inhibitor) in NSCLC patients with various MET mutations
Primary endpoint: overall response (complete or partial response)
Secondary endpoint: duration of response

Key question:

Does Capmatinib show meaningful response in patients with various types of MET mutation?

Reference for additional background, purpose and key messages:

Wolf et al. NEJM 2020, 383:944-957, https://www.nejm.org/doi/full/10.1056/NEJMoa2002787

Task 1:

Complete the Purpose Worksheet (separate handout). It is already half filled.

It is available here as a pdf or word file.

Task 2:

See the main visualization of the study results. Improve it or create your own to display the key message(s).

Handout

This information is also available as a handout